Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Part of paid clinical trials in Red Bank, New Jersey.

Sponsor
Advanced Reconstructive Surgery Alliance
Study ID
NCT07012642
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Lymphedema

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GLP-1 Receptor Agonists — DRUG
    GLP-1 RAs in lymphedema

Study Details

Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.

Key Dates

Start date
Apr 9, 2025
Status verified
Jun 2025
Primary completion
Apr 9, 2027
Completion
Apr 9, 2027

Study Design

Enrollment
110 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study arm
    Participants will received GLP-1 RAs for 6 months to study the effects on lymphedema.

Primary Outcome Measure

Patient reported quality of life outcome using LLIS [ Time Frame: 6 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
River CenterRed BankNew Jersey07701
Giana Truax
[email protected]
8662662577
Saba Tasawar
[email protected]
7327410970
260 Old Hook Rd Suite 304WestwoodNew Jersey07675
Ivette Chacon
[email protected]
848-272-2772
Joseph Dayan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Red Bank, NJ

By research site
River Center· Red Bank, NJ260 Old Hook Rd Suite 304· Westwood, NJ

Related Studies